Receptor flexibility in the in Silico screening of reagents in the S1′ pocket of human collagenase

Journal of Medicinal Chemistry

Volumn 47, Issue 11, 2004, Pages 2761-2767

  Källblad, Per ^a   Todorov, Nikolay P ^a   Willems, Henriëtte M G ^a   Alberts, Ian L ^a  

^a De Novo Pharmaceuticals Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGENASE; REAGENT; RECEPTOR;

ARTICLE; CONFORMATION; DRUG PROTEIN BINDING; ENERGY; NUCLEAR MAGNETIC RESONANCE; PROTEIN STRUCTURE; SCREENING; STRUCTURE ANALYSIS;

APOENZYMES; BINDING SITES; CRYSTALLOGRAPHY, X-RAY; HOLOENZYMES; HUMANS; LIGANDS; MAGNETIC RESONANCE SPECTROSCOPY; MATRIX METALLOPROTEINASE 1; MODELS, MOLECULAR; MOLECULAR CONFORMATION; PHENYL ETHERS; PYRIDINES; SULFONES;

EID: 2442706574     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm031061l     Document Type: Article

References (37)

1. Luong, C.; Miller, A.; Barnett, J.; Chow, J.; Ramesha, C.; Browner, M. F. Flexibility of the NSAID Binding Site in the Structure of Human Cyclooxygenase-2. Nat. Struct. Biol. 1996, 3, 927-933.
2. Cao, Y.; Musah, R.; Wilcox, S.; Goodin, D.; McRee, D. Protein Conformer Selection by Ligand Binding Observed with Crystallography. Protein Sci. 1998, 7, 72-78.
3. Carlson, H. A. Protein Flexibility and Drug Design: How to Hit a Moving Target. Curr. Opin. Chem. Biol. 2002, 6, 447-452.
4. Knegtel, R. M. A.; Kuntz, I. D.; Oshiro, C. M. Molecular Docking of Ensembles of Structures. J. Mol. Biol. 1997, 266, 424-440.
5. Claussen, H.; Buning, C.; Rarey, M.; Lengauer, T. FlexE: Efficient Molecular Docking Considering Protein Structure Variations. J. Mol. Biol. 2001, 308, 377-395.
6. Ota, N.; Agard, D. A. Binding Mode Prediction for a Flexible Ligand in a Flexible Pocket Using Multiconformation Simulated Annealing Pseudo Crystallographic Refinement. J. Mol. Biol. 2001, 314, 607-617.
7. Carlson, H. A.; Masukawa, K. M.; McCammon, J. A. Method for Including the Dynamic Fluctuation of a Protein in Computer-Aided Drug Design. J. Phys. Chem. 1999, 103, 10213-10219.
8. Schnecke, V.; Kuhn, L. A. Virtual Screening with Solvation and Ligand-Induced Complementarity. Perspect. Drug Discovery Des. 2000, 20, 171-190.
9. Anderson, A. C.; O'Niel, R. H.; Surti, T. S.; Stroud, R. M. Approaches to Solving the Rigid Receptor Problem by Identifying a Minimal Set of Flexible Residues during Ligand Docking. Chem. Biol. 2001, 8, 445-457.
10. Leach, A. R. Ligand Docking to Proteins with Discrete Side-Chain Flexibility. J. Mol. Biol. 1994, 235, 345-356.
11. Caflisch, A.; Miranker, A.; Karplus, M. Multiple Copy Simultaneous Search and Construction of Ligands in Binding Sites: Application to Inhibitors of HIV-1 Aspartic Proteinase. J. Med. Chem. 1993, 36, 2142-2167.
12. Teague, S. J. Implications of Protein Flexibility for Drug Design. Nat. Rev. Drug Discovery. 2003, 2, 527-541.
13. Whittaker, M.; Floyd, C. D.; Brown, P.; Gearing, A. J. H. Design and Therapeutic Application of Matrix Metalloproteinase Inhibitors. Chem. Rev. 1999, 99, 2735-2776.
14. Coussence, L. M.; Fingleton, B.; Matrisian, L. M. Matrix Metalloproteinase Inhibitors and Cancer: Trials and Tribulations. Science 2002, 295, 2387-2392.
15. Cleutjens, J. P. The Role of Matrix Metalloproteinases in Heart Disease. Cardiovasc. Res. 1996, 30, 816-821.
16. Beckett, R. P.; Whittaker, M. Matrix Metalloproteinase Inhibitors. Expert Opin. Ther. Pat. 1998, 8, 259-282.
17. Vassiliou, S.; Mucha, A.; Cuniasse, P.; Georgiadis, D.; Lucetlevannier, K.; Beau, F.; Kannan, R.; Murphy, G.; Knauper, V.; Rio, M. C.; et al. Phosphinic Pseudo-Tripeptides as Potent Inhibitors of Matrix Metalloproteinases: a Structure-Activity Study. J. Med. Chem. 1999, 42, 2610-2620.
18. Babine, R. E.; Bender, S. L. Molecular Recognition of Protein-Ligand Complexes: Applications to Drug Design. Chem. Rev. 1997, 97, 1359-1472.
19. Moy, F. J.; Chanda, P. K.; Chen, J. M.; Cosmi, S.; Edris, W.; Skotnicki, J. W.; Powers, R. Solution Structure of the Catalytic Fragment of Human Fibroblast Collagenase Complexed with a Sulfonamide Derivative of a Hydroxamic Acid Compound. Biochemistry 1999, 38, 7085-7096.
20. Lovejoy, B.; Welsh, A. R.; Carr, S.; Luong, C.; Broka, C.; Hendricks, R. T.; Campbell, J. A.; Walker, K. A. M.; Martin, R.; van Wart, H.; et al. Crystal Structures of MMP-1 and -13 Reveal the Structural Basis for Selectivity of Collagenase Inhibitors. Nat. Struct. Biol. 1999, 6, 217-221.
21. Botos, I.; Scapozza, L.; Zhang, D.; Liotta, L. A.; Meyer, E. F. Batimastat, a potent matrix mealloproteinase inhibitor, exhibits an unexpected mode of binding. Proc. Natl. Acad. Sci. U.S.A. 1996, 93, 2749-2754.
22. Meng, Q.; Malinovskii, V.; Huang, W.; Hu, Y.; Chung, L.; Nagase, H.; Bode, W.; Maskos, K.; Brew, K. Residue 2 of TIMP-1 is a major determinant of affinity and specificity for matrix metalloproteinases but effects of substitutions do not correlate with those of the corresponding P1′ residue of substrate. J. Biol. Chem. 1999, 274, 10184-10189.
23. Borkakoti, N.; Winkler, F. K.; Williams, D. H.; Darcy, A.; Broadhurst, M. J.; Brown, P. A.; Johnson, W. H.; Murray, E. J. Structure of the Catalytic Domain of Human Fibroblast Collagenase Complexed with an Inhibitor. Nat. Struct. Biol. 1994, 1, 106-110.
24. Moy, F. J.; Chanda, P. K.; Cosmi, S.; Pisano, M. R.; Urbano, C.; Wilhelm, J.; Powers, R. High-Resolution Solution Structure of the Inhibitor-Free Catalytic Fragment of Human Fibroblast Determined by Multidimensional NMR. Biochemistry 1998, 37, 1495-1504.
25. Källblad, P.; Dean, P. M. Efficient Conformational Sampling of Local Side-Chain Flexibility. J. Mol. Biol. 2003, 326, 1651-1665.
26. Bairoch, A.; Apweiler, R. The SWISS-PROT protein sequence database and its supplement TrEMBL in 2000. Nucleic Acids Res. 2000, 28, 45-48.
27. Maple, J. R.; Dinur, U.; Hagler, E. T. Derivation of Force Fields for Molecular Mechanics and Dynamics from ab Initio Energy Surfaces. Proc. Natl. Acad. Sci. U.S.A. 1988, 85, 5350-5354.
28. Dunbrack, R. L.; Karplus, M. Backbone-Dependent Rotamer Library for Proteins-Application to Side-Chain Prediction. J. Mol. Biol. 1993, 230, 543-574.
29. Dunbrack, R. L.; Cohen, F. E. Bayesian Statistical Analysis of Protein Side-Chain Rotamer Conformations. Protein Sci. 1997, 6, 1661-1681.
30. Bondi, A. van der Waals Volumes and Radii. J. Phys. Chem. 1968, 68, 441-451.
31. Jackson, J. E. A User's Guide to Principal Components; Wiley: New York, 1991.
32. MacPerson, L. J.; Bayburt, E. K.; Capparelli, M. P.; Carroll, B. J.; Goldstein, R.; Justice, M. R.; Zhu, L.; Hu, S.; Melton, R. A.; Fryer, L.; et al. Discovery of CGS 27023A, a Non-Peptidic, Potent, and Orally Active Stromelysin Inhibitor That Blocks Cartilage Degradation in Rabbits. J. Med. Chem. 1997, 40, 2525-2532.
33. Stahl, M.; Todorov, N. P.; James, T.; Mauser, H.; Böhm, H.-J.; Dean, P. M. A Validation Study on the Practical Use of Automated de Novo Design. J. Comput-Aided Mol. Des. 2002, 16, 459-478.
34. Todorov, N. P.; Dean, P. M. Evaluation of a Method for Controlling Molecular Scaffold Diversity in de Novo Ligand Design. J. Comput.-Aided Mol. Des. 1997, 11, 175-192.
35. Schrauber, H.; Eisenhaber, F.; Argos, P. Rotamers: to be or not to be? An Analysis of Amino-Acid Side-Chain Conformations in Globular Proteins. J. Mol. Biol. 1993, 230, 592-612.
36. Böhm, H.-J. The Development of a Simple Empirical Scoring Function To Estimate the Binding Constant for a Protein-Ligand Complex of Known Three-Dimensional Structure. J. Comput.-Aided Mol. Des. 1994, 8, 243-256.
37. Todorov, N. P.; Dean, P. M. A branch-and-bound method for optimal atom-type assignment in de novo ligand design. J. Comput.-Aided Mol. Des. 1998, 12, 335-349.